Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Juweid, Malik E ^a   Stadtmauer, Edward ^b   Hajjar, George ^a   Sharkey, Robert M ^a   Suleiman, Samer ^a   Luger, Selina ^b   Swayne, Lawrence C ^a   Alavi, Abass ^b   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CD22 ANTIGEN; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LL 2 I 131; MONOCLONAL ANTIBODY LL 2 IN 111; MONOCLONAL ANTIBODY LL 2 Y 90; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CLINICAL ARTICLE; CONFERENCE PAPER; DOSIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RELAPSE; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL ADHESION MOLECULES; FEMALE; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; LECTINS; LYMPHOMA, NON-HODGKIN; MALE; MICE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; RECURRENCE; YTTRIUM RADIOISOTOPES;

EID: 0032697615     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. DeNardo, G. L., DeNardo, S. J., O'Grady, L. F., Levy, N. B., Adams, G. P., and Mills, S. L. Fractionated radioimmunotherapy of B-cell malignancies with. 131I-Lym-1. Cancer Res., 50: 1014-1016, 1990.
2. Scheinberg, D., Straus, D., Yeh, S., Divgi, C., Garin-Chesa, P., Graham, M., Pentlow, K., Coit, D., Oettgen, H., and Old, L. A Phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. J. Clin. Oncol., 8: 792-803, 1990.
3. Goldenberg, D. M., Horowitz, J. A., Sharkey, R. M., Hall, T. C., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegel, J. A., Izon, D. O., Burger, K., Swayne, L. C., Belisle, E., Hansen, H. J., and Pinsky, C. M. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol., 9: 548-564, 1991.
4. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
5. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D. C. Fisher, L. D., and Bernstein, I. D. Radiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.
6. Juweid, M., Sharkey, R. M., Markowitz, A., Behr, T., Swayne, L. C., Hansen, H. J., Shevitz, J., Leung, S. O., Rubin, A. D., Herskovic, T., Hanley, D., and Goldenberg, D. M. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, and anti-CD22 monoclonal antibody. Cancer Res., 55 (Suppl.): 5899s-5907s, 1995.
7. Knox, S. J., Goris, M. L., and Trisler, K. 90-Yttrium labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res., 2: 457-470, 1996.
8. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenne, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., and Wahl, R. L. Iodine-131-anti-B1 radioimmunotherapy. J. Clin. Oncol., 14: 1974-1981, 1996.
9. Witzig, T., Wiseman, G., and White, C. IDEC-Y2B8 90-Yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim results of a Phase I/II trial. Blood, 90: 586a, 1997.
10. Pawlak-Byczkowska, E., Hansen, H. J., Dion, A., and Goldenberg, D. M. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res., 49: 4568-4577, 1989.
11. Stein, R., Belisle, E., Hansen, H. J., and Goldenberg, D. M. Epitope spcificity of the anti-B-cell lymphoma monoclonal antibody, LL2. Cancer Immunol. Immunother., 37: 293-298, 1993.
12. Shih, H., Lu, H.-Z., Xuan, H., and Goldenberg, D. M. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody. Int. J. Cancer, 56: 538-545, 1994.
13. Kreitman, R. J., FitzGerald, D. J., Hansen, H., Goldenberg, D. M., and Pastan, I. Cytotoxicity of conjugates between LL2 and derivatives of pseudomonas exotoxin toward B-cell non-Hodgkin's lymphoma. Cancer Res., 53: 819-825, 1993.
14. Mattes, M. J., Griffiths, G. L., Diril, H., Goldenberg, D. M., Ong, G. L., and Shih, L. B. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer (Phila.), 73 (Suppl.): 787s-793s, 1994.
15. Sharkey, R. M., Behr, T. M., Mattes, M. J., Stein, R., Griffiths, G. L., Shih, L. B., Hansen, H. J., Blumenthal, R. D., Dunn, R. M., Juweid, M. E., and Goldenberg, D. M. Advantages of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen. CD22. Cancer Immunol. Immunother., 44: 179-188. 1997.
16. Sharkey, R. M., Motta-Hennessy, C., Gansow, O. A., Brechbiel, M. W., Fand, I., Griffiths, G. L., Jones, A. L., and Goldenberg, D. M. Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonie tumor in nude mice. Int. J. Cancer, 46: 79-85, 1990.
17. Sharkey, R. M., Motta-Hennessy, C., Pawlyk, D., Siegel, J. A., and Goldenberg, D. M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonie tumor xenografts. Cancer Res., 50: 2330-2336, 1990.
18. Leung, S. O., Goldenberg, D. M., Dion, A. S., Pellegrini, M. C., Shevitz, J., Shih, L. B., and Hansen, H. J. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol. Immunol., 32: 1413-1427, 1995.
19. Weadock, K. S., Sharkey, R. M., Varga, D. C., and Goldenberg, D. M. Evaluation of a remote radioiodination system for radioimmunotherapy. J. Nucl. Med., 31: 508-511, 1989.
20. Siegel, J. A., Lee, R. E., Pawlyk, D., Horowitz, J. A., Sharkey, R. M., and Goldenberg, D. M. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int. J. Radiat. Appl. Instrum. Part B. 16: 553-559, 1989.
21. Juweid, M., Sharkey, R. M., Siegel, J. A., Behr, T., and Goldenberg, D. M. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake. Cancer Res., 55 (Suppl.): 5827s-5831s, 1995.
22. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res., 50 (Suppl.): 1039s-1042s, 1990.
23. Loevinger, R., and Berman, M. A Revised Scheme for Calculating the Absorbed Dose from Biologically Distributed Radionuclide. MIRD pamphlet no. 1, revised, 1976.
24. Vose, J., Colcher, D., Bierman, P., Leichner, P., Akabani, G., Harrison, K., Hohenstein, M., Lesser, L., Hammerschaimb, L., and Goldenberg, D. M. I-131-LL2 (anti-CD22) radioimmunotherapy (RIT) of refractory non-Hodgkin's lymphoma (NHL): results of a repetitive dosing trial. J. Nucl. Med., 38: 59P, 1997.
25. Sharkey, R. M., Juweid, M. E., Shevitz, J., Behr, T., Dunn, R., Swayne, L. C., Wong, G. Y., Blumenthal, R. D., Griffiths, G. L., Siegel, J. A., Leung, S.-O., Hansen, H. J., and Goldenberg, D. M. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res., 53 (Suppl.): 5935s-5945s, 1995.